34 search results
Anus
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Colon
21DRA090: A Phase 1a/1b Study of LY3537982 Administered to Patients with KRAS G12C-Mutant Advanced Solid Tumors
Location: Lebanon
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A022101 : A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR), (NCT TBD)
Location: Lebanon
A022104 - The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Location: Lebanon
Checkpoint Immunotherapy for Tumors Common in Fanconi Anemia
Location: Lebanon
Colonoscopy versus Stool-based Testing for Older Adults with a History of Colon Polyps
Location: Lebanon
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-GI008 : Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Esophagus
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Liver
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Digestive Organ
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Pancreas
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A022001 : Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Location: Lebanon
EA2192 : A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Location: Lebanon, St. Johnsbury, VT
Pancreas Cancer Direct Xenograft Program at Dartmouth-Hitchcock Medical Center
Location: Lebanon
S2001 : Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Location: Lebanon, St. Johnsbury, VT
Rectum
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Small Intestine
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Stomach
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
